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Introduction:
Cluster headache (CH) is a primary headache disorder and is characterized by severe unilateral, short-lasting head pain accompanied with autonomic dysfunction. CH is classified into the two subtypes, episodic and chronic CH. There is evidence for the treatment of CH with oxygen inhalation, injectable sumatriptan, 1 intranasal zolmitriptan, 2 intranasal lignocaine and intranasal dihydroergotamine.
Sumatriptan is a 5-HT 1B/1D agonist that has been shown to decrease neural activity of the trigeminal nucleus in animal models and acts on receptors present in the cranial and basilar arteries, leading to vasoconstriction of large cerebral vessels. 3 The recommended daily maximum dosage for oral application is 200 mg, for sc injections 12 mg, for nasal spray 40 mg and for suppository application 50 mg. Generally sumatriptan treatment is well tolerated. vasospasm, myocardial infarction), or hypertensive crises. 4 Very rarely, sumatriptan use might lead to sulfhemoglobinemia. Withdrawal of sumatriptan, which was performed twice, did not change the characteristics of the attacks. Several prophylactic attempts were unsuccessful; the criteria for intractable cluster headache are fulfilled. 6 Due to the high number of attacks, the use of sumatriptan injections was between 2 (=12mg) and 37 (=222mg) per day. In the interval between CH attacks, she was free of any headache.
No side effects of therapy were reported, no severe adverse events occurred. Repeated clinical and laboratory examinations and ECGs showed normal results. For fifteen years sumatriptan treatment still is effective in aborting CH attacks.
Conclusions
To our best knowledge this is the first report on a documented long-term excessive triptan overdose usage for 15 years. Although criteria for cluster headache are fulfilled 7 , the high frequency of attacks in our patient is an atypical feature for CH and suggestive of chronic paroxysmal headache (CPH). In some cases, CPH could have been successfully treated with sumatriptan, too. 8 Data on long-term use (over 12 months) and overuse of sumatriptan in cluster headache are lacking. In a study by Goebel et al., 9 no decline in efficacy occurred during one year of conventional treatment. Adverse events were reported by 2/3 of the patients, but where overall of minor character. In a study with thirteen sumatriptan overuse CH patients, Centonze et al. 10 found a low incidence of adverse events or development of tolerance. In a population-based study 11 a minority of heavy sumatriptan users (with more than two defined daily dosages of sumatriptan (=12 mg s.c.) for the treatment of acute migraine were found. Rebound headaches or an incorrect use as migraine prophylaxis were suggested as cause of the overuse.
Our patient did not develop any transformation of her headaches, which in line with the published literature.
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Our case is compatible with above findings of a low development of tolerance over time in CH patients and indicates good tolerability and safety even in dosages well over the recommended daily maximum.
